Market Place
Sourcing Support
Armata Pharma Reports Results from AP-PA02 Phase 2 Study
19 Dec 2024 //
PR NEWSWIRE
Armata Pharma CEO Dr. Deborah Birx to Present at Phage Futures
19 Nov 2024 //
PR NEWSWIRE
Armata Pharma Announces Q3 2024 Results & Update
13 Nov 2024 //
PR NEWSWIRE
Armata Pharma Completes Enrollment for AP-SA02 Bacteremia Study
12 Nov 2024 //
PR NEWSWIRE
Armata Pharmaceuticals Announces Structural Biology Publication
30 Oct 2024 //
PR NEWSWIRE
Armata Pharmaceuticals Joins H.C. Wainwright Global Investment Conference
05 Sep 2024 //
PR NEWSWIRE
Armata Pharmaceuticals To Present At Military Health Research Symposium
26 Aug 2024 //
PR NEWSWIRE
Armata Pharmaceuticals Reports Q2 2024 Results And Corporate Update
13 Aug 2024 //
PR NEWSWIRE
Armata Completes Enrollment For Phase 2 Study Of Inhaled AP-PA02
11 Jul 2024 //
PR NEWSWIRE
Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024
10 Jul 2024 //
PR NEWSWIRE
Armata Pharmaceuticals Q1 2024 Results, Corporate Update
07 May 2024 //
PR NEWSWIRE
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results
21 Mar 2024 //
PR NEWSWIRE
Armata Pharma Announces $35 Million Secured Credit Agreement with Innoviva
04 Mar 2024 //
PR NEWSWIRE
Armata Announces Presentation at the 6th Annual Therapy Summit
21 Feb 2024 //
PR NEWSWIRE
Armata Announces Third Quarter 2023 Results and Provides Corporate Update
14 Nov 2023 //
PR NEWSWIRE
Armata Announces Presentation of Topline Data from SWARM-P.a. Study
30 Oct 2023 //
PR NEWSWIRE
Armata Announces First Patient Dosed in Phase 2a of Study of AP-SA02
26 Sep 2023 //
PR NEWSWIRE
Armata Pharma to Participate in the Cantor Global Healthcare Conference
21 Sep 2023 //
PR NEWSWIRE
Armata Announces Second Quarter 2023 Results and Provides Corporate Update
14 Aug 2023 //
PR NEWSWIRE
Armata Announces Presentation Detailing Results from Phase 1b/2a SWARM Trial
31 May 2023 //
PR NEWSWIRE
Armata Pharmaceuticals Announces 1Q 2023 Results and Provides Corporate Update
11 May 2023 //
PR NEWSWIRE
Armata Announces Fourth Quarter and Full-Year 2022 Results
16 Mar 2023 //
PR NEWSWIRE
Armata Pharmaceuticals Announces Positive Topline Data from Phase 1b/2a SWARM
06 Mar 2023 //
PR NEWSWIRE
Armata Announces Closing of $30M Convertible Credit Agreement with Innoviva
10 Jan 2023 //
PR NEWSWIRE
Armata Pharma completes phase 1b/2a `SWARM-P.a.` study of inhaled AP-PA02
24 Dec 2022 //
PHARMABIZ
Armata Pharmaceuticals Announces Completion of its Phase 1b/2a
22 Dec 2022 //
PRNEWSWIRE
Armata concludes Phase Ib/IIa Pseudomonas aeruginosa infection therapy trial
21 Dec 2022 //
CLINICALTRIALSARENA
Armata to Participate in H.C. Wainwright Investor Conference on Bacteriophage
28 Nov 2022 //
PRNEWSWIRE
Armata Pharmaceuticals Announces 3Q 2022 Results
09 Nov 2022 //
PRNEWSWIRE
Armata Pharma Announces Clearance of IND for Prosthetic Joint Infections
01 Aug 2022 //
PRNEWSWIRE
Armata Pharma Announces First Patient Dosed in Phase 1b/2a `diSArm` Study
23 May 2022 //
PRNEWSWIRE
Armata Pharmaceuticals Announces First Quarter 2022 Results
12 May 2022 //
PRNEWSWIRE
Armata Pharma Closes Final Tranche of $45M Private Placement with Innoviva
31 Mar 2022 //
PRNEWSWIRE
Armata Pharma says Q4 and FY 2021 Results
17 Mar 2022 //
PRNEWSWIRE
FDA Clears Armata`s IND to Initiate Phase 2 Clinical Trial of AP-PA02
22 Feb 2022 //
PRNEWSWIRE
Armata Pharmaceuticals to Participate in Two Upcoming Investor Conferences
17 Feb 2022 //
PRNEWSWIRE
Armata Provides Regulatory and Clinical Update Reflecting Sustained Progress
18 Nov 2021 //
PRNEWSWIRE
Armata Announces Q3 Results and Provides General Corporate Update
10 Nov 2021 //
PRNEWSWIRE
Armata Enters Lease to Build State-of-the-Art R&D and GMP Manufacturing Facility
02 Nov 2021 //
PRNEWSWIRE
Real-world evidence on Gilead`s Biktarvy confirms high efficacy; & more
29 Oct 2021 //
ENDPTS
Armata Pharmaceuticals Announces Chief Executive Officer Transition
02 Aug 2021 //
PRNEWSWIRE
Armata Announces First Quarter Results and Provides General Corporate
13 May 2021 //
PRNEWSWIRE
Armata Pharma Announces Q4 and Full Year 2020 Results
18 Mar 2021 //
PRNEWSWIRE
Armata Pharmaceuticals Announces the Addition of Robin C. Kramer
09 Dec 2020 //
PRNEWSWIRE
Armata Pharmaceuticals Issues Letter to Shareholders
29 Oct 2020 //
PRNEWSWIRE
Armata Appoints Mina Pastagia, MD, MS as Vice President of Clinical Development
26 Oct 2020 //
PRNEWSWIRE
Armata Announces Clearance of Application to Initiate Ph1b/2a Clinical Trial
15 Oct 2020 //
PRNEWSWIRE
Armata Pharmaceuticals Announces $15 M Award from the U.S. (DoD) for Development
17 Jun 2020 //
PR NEWSWIRE
Armata Announces $15 M Award from the U.S. Department of Defense (DoD)
16 Jun 2020 //
PRNEWSWIRE
Armata Pharma to Participate in the Maxim Group M-Vest Infectious Disease
28 Apr 2020 //
PR NEWSWIRE
Armata Pharma Announces Closing of Second Tranche of $25 M Agreement Innoviva
30 Mar 2020 //
PR NEWSWIRE
Armata Pharmaceuticals Announces up to $5M Therapeutics Development
18 Mar 2020 //
PRNEWSWIRE
Armata`s Announces Closing of First Tranche of Recently Executed $25M
13 Feb 2020 //
PR NEWSWIRE
